Welcome to our dedicated page for GRAY news (Ticker: GRAY), a resource for investors and traders seeking the latest updates and insights on GRAY stock.
The GRAY news archive on Stock Titan covers the historical public communications of Graybug Vision, Inc., which previously traded on Nasdaq under the symbol GRAY. Company press releases describe Graybug as a clinical-stage biopharmaceutical company focused on developing medicines for ocular diseases, including vision-threatening disorders of the retina, optic nerve, and cornea.
News items in this archive include updates on Graybug’s investigational pipeline, such as GB-102 for wet age-related macular degeneration, GB-401 for primary open-angle glaucoma, and gene therapy and sustained-release candidates like GB-501, GB-601, and GB-701. Releases also document participation in ophthalmology conferences and scientific meetings where the company presented preclinical and clinical data related to its programs.
Another important theme in the GRAY news history is corporate strategy. Graybug announced a review of strategic alternatives, outlining potential options such as a merger or company sale, followed by cost-containment measures and changes to its development activities. Subsequent news detailed a definitive merger agreement with CalciMedica Inc., an all-stock transaction intended to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on life-threatening inflammatory diseases.
The archive further records the name and trading symbol change from Graybug Vision, Inc. (GRAY) to CalciMedica, Inc. (CALC) on the Nasdaq Global Market, undertaken in connection with the merger. Readers using this page can follow the historical progression from Graybug’s focus on ophthalmology through its strategic review and combination with CalciMedica. For ongoing developments after the name and ticker change, company communications direct attention to CalciMedica, Inc. under the symbol CALC.
Investors and researchers can use this GRAY news collection as a historical reference to understand Graybug’s former pipeline, its clinical and preclinical milestones, and the sequence of events leading to its merger and rebranding as CalciMedica, Inc.
Graybug Vision, a clinical-stage biopharmaceutical company, announced its participation in the ASCRS Annual Meeting in Washington, D.C., from April 22-26, 2022. The company will present on the intrastromal delivery of AAV-IDUA for treating MPS1-associated corneal clouding, led by Dr. Parisa Zamiri on April 25. Graybug's candidates focus on ocular diseases, with its most advanced drug, GB-102, targeting wet age-related macular degeneration. The presentation will be accessible on their website post-event.
Graybug Vision, Inc. (Nasdaq: GRAY) announced the appointment of Dirk Sauer, PhD, to its Board of Directors effective April 13, 2022. He replaces Gerald Cagle, PhD, who is retiring after eight years but will remain as an advisor. Sauer brings over 30 years of experience in ophthalmic drug development, and he will lead the Science and Innovation Committee to guide the company's research and development strategies. Graybug focuses on innovative treatments for ocular diseases, with candidates like GB-102 for wet AMD and GB-401 for glaucoma.
Graybug Vision, Inc. (Nasdaq: GRAY) announced key updates on its clinical pipeline aimed at ocular diseases. The Phase 2 trial for GB-102 in wet AMD is set for Q4 2022, while a Phase 1 trial for glaucoma (GB-401) is anticipated in Q1 2023. Additionally, the acquisition of a corneal gene therapy program (GB-501) is underway, with data expected in Q4 2023. Current cash is projected to sustain operations into Q4 2023. A virtual Investor R&D Day is scheduled for March 30, 2022, to present these developments.
Graybug Vision, Inc. (NASDAQ: GRAY) will host a virtual Investor R&D Day on March 30, 2022, from 11 a.m. to 12:45 p.m. ET. The event will feature expert presentations on ocular diseases, including wet age-related macular degeneration and primary open-angle glaucoma. Graybug aims to provide insights into its advancing pipeline and drug discovery programs, focusing on new assets in inherited corneal and retinal diseases. Registration is available through the company’s website, and participants can join via phone. Graybug is dedicated to developing transformative ocular disease treatments.
Graybug Vision, Inc. (NASDAQ: GRAY) reported a net loss of $35.8 million for 2021, up from $27.5 million in 2020. R&D expenses decreased to $18.9 million from $21.0 million, while general and administrative expenses rose notably to $17.0 million. Key advancements include the completion of the ALTISSIMO Phase 2b trial for GB-102, demonstrating a six-month treatment duration in 48% of patients. The company is preparing for a new Phase 2 trial and aims to initiate the GB-401 Phase 1 trial in 2023. The upcoming R&D Day is scheduled for March 30, 2022.
Graybug Vision, Inc. (Nasdaq: GRAY) announced participation in three key medical and investor conferences. On February 11, 2022, Dr. Veeral Sheth will present on GB-102's safety/durability in treating wet age-related macular degeneration. Fred Guerard will discuss advances in GB-401 for glaucoma during the New Horizons Forum on the same day. Additionally, Guerard will partake in a fireside chat at the SVB Leerink Global Healthcare Conference on February 17, 2022. Graybug is dedicated to developing innovative treatments for retinal and optic nerve diseases, with a focus on extended drug delivery technologies.
Graybug Vision, Inc. (NASDAQ: GRAY) announced the hiring of six new employees to bolster its Research & Development, Regulatory Affairs, and Program Management teams. CEO Fred Guerard emphasized the importance of expanding their ophthalmology team to enhance their clinical pipeline in 2022. Key hires include Fang Li, VP of Regulatory Affairs, and Ali Kakavand, VP of Program Management, both bringing over 20 years of relevant experience. Additionally, the company granted inducement options for 234,200 shares at an exercise price of $1.55, aligned with its strategic growth initiatives.
Graybug Vision, a clinical-stage biopharmaceutical company focused on retinal and optic nerve diseases, announced that CEO Fred Guerard will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The chat will be available on November 22, 2021, at 10 a.m. ET. Investors can also schedule 1x1 meetings through Piper Sandler. Graybug's lead candidate, GB-102, targets retinal diseases with a six-month or longer dosing regimen, while GB-401 is aimed at glaucoma treatments. For more details, visit Graybug's website.
Graybug Vision, Inc. (NASDAQ: GRAY) reported its financial results for the three and nine months ended September 30, 2021, revealing a net loss of $8.0 million for Q3 2021, up from $4.7 million in Q3 2020. R&D expenses decreased to $4.0 million, while G&A expenses rose to $4.0 million. For the nine-month period, the net loss was $27.1 million, compared to $18.4 million in 2020. The company is advancing its GB-102 wet AMD treatments and holds $72.6 million in cash, expected to fund operations into 2023.
BALTIMORE, Nov. 01, 2021 - Graybug Vision (Nasdaq: GRAY) announced two key clinical data presentations at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting, scheduled for November 12-15 in New Orleans. The CEO, Fred Guerard, will present a company overview at the Eyecelerator@AAO event on November 11, while Dr. Arshad Khanani will share findings on the safety and durability of GB-102 for wet age-related macular degeneration. Additionally, Dr. Veeral Sheth will discuss GB-102's late-breaking results at the Retina Subspecialty Day on November 13.
FAQ
What is the market cap of GRAY (GRAY)?
